Drug intelligence / Profile preview

TR-301

Development stage: Preclinical
Lead developer: Terrestrial Bio
Modality: Peptides
Administration: Transdermal

Overview

TR-301 is a preclinical-stage dual amylin and glucagon-like peptide-1 (GLP-1) receptor agonist being developed by Terrestrial Bio (formerly Vaxess Technologies) for the treatment of obesity. The drug is delivered via a proprietary silk-based microarray patch (MAP) technology, which allows for transdermal administration of biologics. By targeting both the amylin and GLP-1 receptors, TR-301 aims to leverage synergistic effects on appetite suppression and glycemic control. The MAP delivery system is designed to provide a convenient, shelf-stable, and potentially more tolerable alternative to traditional subcutaneous injections.

Other names: dual amylin/GLP-1 receptor agonist MAP

Targets

GLP1R (GLP-1R)AMY receptor (Calcitonin receptor (with ramps))

Beyond the preview

Go deeper on TR-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TR-301.

Explore the full profile